HLA-Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplant Cyclophosphamide after Busulfan-Containing Reduced-Intensity Conditioning

Biology of Blood and Marrow Transplantation

Volumn 21, Issue 9, 2015, Pages 1646-1652

  Sugita, Junichi ^a   Kawashima, Naomi ^b   Fujisaki, Tomoaki ^c   Kakihana, Kazuhiko ^d   Ota, Shuichi ^e   Matsuo, Keitaro ^f   Miyamoto, Toshihiro ^g   Akashi, Koichi ^g   Taniguchi, Shuichi ^h   Harada, Mine ⁱ   Teshima, Takanori ^a  

^a HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^c MATSUYAMA RED CROSS HOSPITAL   (Japan)

^d TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^e SAPPORO HOKUYU HOSPITAL   (Japan)

^f KYUSHU UNIVERSITY   (Japan)

^g KYUSHU UNIVERSITY HOSPITAL   (Japan)

^h TORANOMON HOSPITAL   (Japan)

ⁱ Karatsu Higashimatsuura Medical Center   (Japan)

Author keywords

Busulfan; HLA haploidentical transplantation; Post transplant cyclophosphamide; Reduced intensity conditioning

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; MYCOPHENOLATE MOFETIL; TACROLIMUS; HLA ANTIGEN;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE LYMPHOBLASTIC LEUKEMIA; ACUTE MYELOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; CANCER PATIENT; CANCER RECURRENCE; CAUSE OF DEATH; CHRONIC GRAFT VERSUS HOST DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; DISEASE FREE SURVIVAL; DRUG SAFETY; DRUG SCREENING; ENGRAFTMENT; FEMALE; FOLLICULAR LYMPHOMA; FOLLOW UP; GRAFT SURVIVAL; HAPLOIDENTICAL PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNOPROPHYLAXIS; INCIDENCE; INFECTION; LARGE CELL LYMPHOMA; LIVER VENOOCCLUSIVE DISEASE; LYMPHOBLASTOMA; MALE; MULTICENTER STUDY; MULTIPLE ORGAN FAILURE; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE NEOPLASM; NEUTROPHIL; OVERALL SURVIVAL; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PHASE 2 CLINICAL TRIAL; PROSPECTIVE STUDY; REDUCED INTENSITY CONDITIONING; REMISSION; CLINICAL TRIAL; HEMATOLOGIC NEOPLASMS; MIDDLE AGED; MORTALITY; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

ADOLESCENT; ADULT; AGED; BUSULFAN; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; FEMALE; HEMATOLOGIC NEOPLASMS; HLA ANTIGENS; HUMANS; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION CONDITIONING;

EID: 84938909900     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2015.06.008     Document Type: Article

References (36)

1. Beatty P.G., Clift R.A., Mickelson E.M., et al. Marrow transplantation from related donors other than HLA-identical siblings. N Engl J Med 1985, 313:765-771.
2. Powles R.L., Morgenstern G.R., Kay H.E., et al. Mismatched family donors for bone-marrow transplantation as treatment for acute leukaemia. Lancet 1983, 1:612-615.
3. Anasetti C., Beatty P.G., Storb R., et al. Effect of HLA incompatibility on graft-versus-host disease, relapse, and survival after marrow transplantation for patients with leukemia or lymphoma. Hum Immunol 1990, 29:79-91.
4. Aversa F., Tabilio A., Velardi A., et al. Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype. N Engl J Med 1998, 339:1186-1193.
5. Luznik L., O'Donnell P.V., Symons H.J., et al. HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide. Biol Blood Marrow Transplant 2008, 14:641-650.
6. Kasamon Y.L., Luznik L., Leffell M.S., et al. Nonmyeloablative HLA-haploidentical bone marrow transplantation with high-dose posttransplantation cyclophosphamide: effect of HLA disparity on outcome. Biol Blood Marrow Transplant 2010, 16:482-489.
7. Munchel A., Kesserwan C., Symons H.J., et al. Nonmyeloablative, HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide. Pediatr Rep 2011, 3(Suppl. 2):e15.
8. Munchel A.T., Kasamon Y.L., Fuchs E.J. Treatment of hematological malignancies with nonmyeloablative, HLA-haploidentical bone marrow transplantation and high dose, post-transplantation cyclophosphamide. Best Pract Res Clin Haematol 2011, 24:359-368.
9. Al-Homsi A.S., Roy T.S., Cole K., et al. Post-transplant high-dose cyclophosphamide for the prevention of graft-versus-host disease. Biol Blood Marrow Transplant 2015, 21:604-611.
10. Berenbaum M.C., Brown I.N. Prolongation of homograft survival in mice with single doses of cyclophosphamide. Nature 1963, 200:84.
11. Luznik L., Jalla S., Engstrom L.W., et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood 2001, 98:3456-3464.
12. Luznik L., Engstrom L.W., Iannone R., Fuchs E.J. Posttransplantation cyclophosphamide facilitates engraftment of major histocompatibility complex-identical allogeneic marrow in mice conditioned with low-dose total body irradiation. Biol Blood Marrow Transplant 2002, 8:131-138.
13. Ross D., Jones M., Komanduri K., Levy R.B. Antigen and lymphopenia-driven donor T cells are differentially diminished by post-transplantation administration of cyclophosphamide after hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013, 19:1430-1438.
14. Bashey A., Zhang X., Sizemore C.A., et al. T-cell-replete HLA-haploidentical hematopoietic transplantation for hematologic malignancies using post-transplantation cyclophosphamide results in outcomes equivalent to those of contemporaneous HLA-matched related and unrelated donor transplantation. J Clin Oncol 2013, 31:1310-1316.
15. Allogeneic peripheral blood stem-cell compared with bone marrow transplantation in the management of hematologic malignancies: an individual patient data meta-analysis of nine randomized trials. J Clin Oncol 2005, 23:5074-5087. Stem Cell Trialists' Collaborative Group.
16. Mielcarek M., Storer B., Martin P.J., et al. Long-term outcomes after transplantation of HLA-identical related G-CSF-mobilized peripheral blood mononuclear cells versus bone marrow. Blood 2012, 119:2675-2678.
17. Aversa F., Reisner Y., Martelli M.F. The haploidentical option for high-risk haematological malignancies. Blood Cells Mol Dis 2008, 40:8-12.
18. Armand P., Kim H.T., Logan B.R., et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood 2014, 123:3664-3671.
19. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995, 15:825-828.
20. Filipovich A.H., Weisdorf D., Pavletic S., et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease. I. Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2005, 11:945-956.
21. Gooley T.A., Leisenring W., Crowley J., et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999, 18:695-706.
22. Fine J.P., Gray R.J. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999, 94:496-509.
23. Kanda Y. Investigation of the freely available easy-to-use software "EZR" for medical statistics. Bone Marrow Transplant 2013, 48:452-458.
24. Jagasia M., Arora M., Flowers M.E.D., et al. Risk factors for acute GVHD and survival after hematopoietic cell transplantation. Blood 2012, 119:296-307.
25. Nakasone H., Fukuda T., Kanda J., et al. Impact of conditioning intensity and TBI on acute GVHD after hematopoietic cell transplantation. Bone Marrow Transplant 2015, 50:559-565.
26. Solomon S.R., Sizemore C.A., Sanacore M., et al. Haploidentical transplantation using T cell replete peripheral blood stem cells and myeloablative conditioning in patients with high-risk hematologic malignancies who lack conventional donors is well tolerated and produces excellent relapse-free survival: results of a prospective phase II trial. Biol Blood Marrow Transplant 2012, 18:1859-1866.
27. Raiola A.M., Dominietto A., Ghiso A., et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantation cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant 2013, 19:117-122.
28. Raj K., Pagliuca A., Bradstock K., et al. Peripheral blood hematopoietic stem cells for transplantation of hematological diseases from related, haploidentical donors after reduced-intensity conditioning. Biol Blood Marrow Transplant 2014, 20:890-895.
29. Bhamidipati P.K., DiPersio J.F., Stokerl-Goldstein K., et al. Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplant 2014, 49:1124-1126.
30. Castagna L., Crocchiolo R., Fürst S., et al. Bone marrow compared with peripheral blood stem cells for haploidentical transplantation with a nonmyeloablative conditioning regimen and post-transplantation cyclophosphamide. Biol Blood Marrow Transplant 2014, 20:724-729.
31. Reagan J.L., Fast L.D., Safran H., et al. Cellular immunotherapy for refractory hematological malignancies. J Transl Med 2013, 11:150.
32. O'Donnell P., Raj K., Pagliuca A. High fever occurring 4 to 5 days post-transplant of haploidentical bone marrow or peripheral blood stem cells after reduced-intensity conditioning associated with the use of post-transplant cyclophosphamide as prophylaxis for graft-versus-host disease. Biol Blood Marrow Transplant 2015, 21:197-198.
33. Colvin G.A., Berz D., Ramanathan M., et al. Nonengraftment haploidentical cellular immunotherapy for refractory malignancies: tumor responses without chimerism. Biol Blood Marrow Transplant 2009, 15:421-431.
34. Nomoto K., Eto M., Yanaga K., et al. Interference with cyclophosphamide-induced skin allograft tolerance by cyclosporin A. J Immunol 1992, 149:2668-2674.
35. McCurdy S.R., Kanakry J.A., Showel M.M., et al. Risk-stratified outcomes of nonmyeloablative, HLA-haploidentical BMT with high-dose posttransplantation cyclophosphamide. Blood 2015, 125:3024-3031.
36. Roberto A., Castagna L., Zanon V., et al. Role of naive-derived T memory stem cells in T-cell reconstitution following allogeneic transplantation. Blood 2015, 125:2855-2864.